Hepatitis A vaccine inactivated - GlaxoSmithKline

Drug Profile

Hepatitis A vaccine inactivated - GlaxoSmithKline

Alternative Names: Havrix; Havrix Junior®; Havrix Monodose®

Latest Information Update: 23 Mar 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Hepatitis A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis A

Most Recent Events

  • 23 Nov 2006 SBL Vaccin AB has been acquired by Crucell
  • 21 Oct 2005 The US FDA has approved the expanded use of the Hepatitis A vaccine inactivated in children aged 12 months and older
  • 26 Aug 2003 PowderJect Pharmaceuticals has been acquired by Chiron Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top